Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CIRM tells oversight committee it is expanding trials, workforce programs and patient support while addressing performance-audit findings
Summary
CIRM updated the Citizens Financial Accountability Oversight Committee on strategic priorities under Prop 14, reporting expanded awards and clinical activity, new education and equity efforts, a patient-support program managed by Avarsana, and a series of management actions in response to recent performance-audit findings on governance, procurement, data and HR.
The California Institute for Regenerative Medicine (CIRM) presented a broad strategic update May 29 to the Citizens Financial Accountability Oversight Committee, outlining priorities for deploying Prop 14 funding, education and workforce programs, clinical trials and early-stage commercialization efforts while describing steps taken to address findings in a recent performance audit.
Dr. Jonathan Thomas, speaking for CIRM, summarized the agency’s mission "accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and the world," reviewed CIRM’s history under Propositions 71 and 14, and described program pillars that include basic research, translational work and clinical trials. He told the Committee that draft slides in the packet showed CIRM had put out roughly "$4,100,000,000.0 in grants to date" (figures were noted as drafted earlier in the year and subject to update) and that Prop 14 included a $1.5 billion target for neurological disorders.
On clinical programs and commercialization, Dr. Thomas emphasized…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
